Barr Labs Approved to Manufacture Generic Xanax XR
Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.’s XANAX XR(R) (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The Company intends to launch its product immediately.
XANAX XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
Barr’s Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.
Barr Pharmaceuticals, Inc. is a holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals.